170 related articles for article (PubMed ID: 837637)
1. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
2. Steady state kinetics of pyridostigmine in myasthenia gravis.
Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
[TBL] [Abstract][Full Text] [Related]
3. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
4. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
[TBL] [Abstract][Full Text] [Related]
5. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
6. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration.
Chan K; Davison SC; Dehghan A; Hyman N
Methods Find Exp Clin Pharmacol; 1981; 3(5):291-6. PubMed ID: 7329157
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
8. Malabsorption of pyridostigmine in patients with myasthenia gravis.
Cohan SL; Dretchen KL; Neal A
Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
[TBL] [Abstract][Full Text] [Related]
9. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
[TBL] [Abstract][Full Text] [Related]
10. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
Davison SC; Hyman NM; Dehghan A; Chan K
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of pyridostigmine.
Cohan SL; Pohlmann JL; Mikszewski J; O'Doherty DS
Neurology; 1976 Jun; 26(6 PT 1):536-9. PubMed ID: 945494
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
[TBL] [Abstract][Full Text] [Related]
14. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
[No Abstract] [Full Text] [Related]
15. Pyridostigmine levels in myasthenia gravis.
Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
[No Abstract] [Full Text] [Related]
16. Continuous infusion of pyridostigmine in the management of myasthenic crisis.
Saltis LM; Martin BR; Traeger SM; Bonfiglio MF
Crit Care Med; 1993 Jun; 21(6):938-40. PubMed ID: 8504663
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and oral bioavailability of pyridostigmine in man.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO
Eur J Clin Pharmacol; 1980 Nov; 18(5):423-8. PubMed ID: 7439266
[TBL] [Abstract][Full Text] [Related]
18. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
Henze T; Nenner M; Michaelis HC
J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring].
Henze T
Fortschr Neurol Psychiatr; 1996 Mar; 64(3):110-21. PubMed ID: 8900891
[TBL] [Abstract][Full Text] [Related]
20. Renal clearance of pyridostigmine in patients with myasthenia gravis.
Chan K; Calvey TN
Eur Neurol; 1977; 16(1-6):69-72. PubMed ID: 615720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
